MacroGenics Announces Timing for Third Quarter 2013 Financial Results and Conference Call Read more about MacroGenics Announces Timing for Third Quarter 2013 Financial Results and Conference Call
MacroGenics Announces Closing of Initial Public Offering and Full-Exercise of Over-Allotment Option Read more about MacroGenics Announces Closing of Initial Public Offering and Full-Exercise of Over-Allotment Option
MacroGenics Announces Pricing of Initial Public Offering Read more about MacroGenics Announces Pricing of Initial Public Offering
Neose Technologies and MacroGenics Sign Research Collaboration and License Agreement Read more about Neose Technologies and MacroGenics Sign Research Collaboration and License Agreement
Genzyme, MacroGenics Announce Joint Effort to Develop New Therapies for Immune-Mediated Diseases Read more about Genzyme, MacroGenics Announce Joint Effort to Develop New Therapies for Immune-Mediated Diseases
MacroGenics Raises $13.5 Million and Appoints President and CEO Read more about MacroGenics Raises $13.5 Million and Appoints President and CEO
MacroGenics Acquires Eliance, Inc., and Establishes Partnership in Immunotherapeutics with UT Southwestern. Read more about MacroGenics Acquires Eliance, Inc., and Establishes Partnership in Immunotherapeutics with UT Southwestern.
HHS Names UTMB, Seven Others as New Regional Centers To Focus on Biodefense Research Read more about HHS Names UTMB, Seven Others as New Regional Centers To Focus on Biodefense Research
MacroGenics Inc. To License Novel Monoclonal Antibody Target From OriGene Technologies, Inc. Read more about MacroGenics Inc. To License Novel Monoclonal Antibody Target From OriGene Technologies, Inc.